Clinical Trials List
2022-02-01 - 2026-03-30
Phase I/II
Recruiting4
ICD-10C67.9
Malignant neoplasm of bladder, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9188.9
Malignant neoplasm of bladder, part unspecified
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- - - 無
- Ying-Chun Shen 無
- YI-KAI CHANG 無
- Yeong-Shiau Pu 無
- YU-CHUAN LU 無
- JIAN-HUA HONG 無
- - - 無
- JHE-CYUAN GUO 無
- FU-JEN HSUEH 無
- CHUNG-HSIN CHEN 無
- PO-MING CHOW 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yen-Hwa Chang 無
- Tzu-Hao Huang 無
- Chueh-Chuan Yen 無
- Yu-Hua Fan 無
- Ming-Hsuan Ku 無
- 陳威任 無
- 潘競成 無
- Jia-An Hong 無
- I-Shen Huang 無
- Yi-Hsiu Huang 無
- Tzu-chun Wei 無
- Jiun-I Lai 無
- Tzu-Hsiang Hsu 無
- Tzu-Ping Lin 無
- Mu-Hsin Chang 無
- Chih-Chieh Lin 無
- William Huang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Hung-Lung Ke 無
- Tsu-Ming Chien 無
- Ching-Chia Li 無
- Tsung-Yi Huang 無
- 黃俊農 無
- Hsiang Ying Lee 無
- 阮雍順 無
- Sheng-Chen Wen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
150-300 participants
